Hana Biosciences, Inc. Earnings Conference Call (Q1 2008)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other May 13 Calls Today's Calls

Call Details Hana Biosciences, Inc. Earnings Conference Call (Q1 2008) Tue, May 13, 2008, 5:00 pm Eastern Listen to the archived event audio About Hana Biosciences, Inc. (NasdaqGM:HNAB) Hana Biosciences, Inc., a development stage biopharmaceutical company, focuses on acquiring, developing, and commercializing innovative products for the foundation of cancer care. The company develops a pipeline of oncology based drug candidates, including therapeutic product candidates and a supportive care product candidate to treat or prevent a serious side effect caused by therapeutic cancer treatments. The company's therapeutic products utilize its nanoparticle OPTISOME technology and includes Marqibo, which utilizes the anti-cancer drug vincristine currently in development for the treatment of acute lymphoblastic leukemia, and metastatic uveal melanoma; Alocrest, which utilizes the anti-cancer drug vinorelbine for the treatment of solid tumors, such as NSCLC and breast cancer; and Brakiva, which utilizes the anti-cancer drug topotecan. Hana's supportive care product is Menadione for the prevention and/or treatment of skin rash associated with the use of epidermal growth factor receptor inhibitors. The company was founded in 2002 and is headquartered in South San Francisco, California. More Info: Quote | Profile | Reports | Research | Msgs | Insider | Financials | Analyst Ratings